CORRECTING and REPLACING: Advicenne to Host a Conference Call on September 12, 2018 at 6 PM to Comment Its Recent Developments
Sep. 11, 2018
NÎMES, France--(BUSINESS WIRE)--Sep 11, 2018--Regulatory News:
This replaces the announcement made at 06:45 pm CEST on 09/11/2018 due to the following corrections: correction in the title.
Advicenne to Host a Conference Call on September 12, 2018 at 6 PM to Comment Its Recent Developments
Advicenne (Euronext: ADVIC), a specialty pharmaceutical company focused on the development of pediatric-friendly therapeutics for the treatment of orphan renal and neurological diseases, today announced that the management of Advicenne will host a conference call on Wednesday September 12, 2018 at 6:00 pm (CEST) to comment its recent developments.
Conference call information:
Date: Wednesday September 12, 2018
Time: 6:00 pm (CEST) / 12:00 pm (ET)
Dial in: +33 172727403 (France) / +1 6467224916 (U.S.) / +44 2071943759 (UK)
PIN code: 22898784#
A presentation will be available, before the start of the conference call, in the Investors section of the Advicenne website ( http://advicenne.com/investors/about-advicenne/letter-from-the-ceo/ )
A recording of the conference call will also be available on replay.
Replay number: +33 170710160 (France) / +1 6467224969 (U.S.) /+44 2033645147 (UK)
Replay code: 418787798#
Advicenne (Euronext: ADVIC) is a pharmaceutical company developing pediatric-friendly therapeutics for the treatment of orphan renal and neurological diseases. The Company’s lead product is ADV7103 which has demonstrated positive results in a European pivotal phase 3 study in children and adults with distal Tubular Renal Acidosis (dTRA), is also being developed for a second indication, Cystinuria, an inherited renal tubulopathy.
Advicenne is planning to file ADV7103 for market authorization for dRTA in Europe in H2 2018 and anticipates its commercial launch in 2020 in Europe. In the United States, FDA has cleared its Investigational New Drug (IND) application to commence pivotal phase 3 clinical trial assessing ADV7103 in dRTA patients. Commercial launch in the United States is anticipated in 2021.
Advicenne is listed on the regulated market of Euronext in Paris (ISIN: FR0013296746; Euronext ticker: ADVIC). The Company, which was established in 2007, is headquartered in Nîmes, France.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180911005789/en/
Luc-André Granier, Sarah Delbaere, Julie Rachline
+33 (0)4 66 05 54 20
US Investor Relations
Rx Communications Group, LLC
Caroline Carmagnol & Tatiana Vieira
+33 (0)1 44 54 36 66
Emmanuel Huynh & Alexia Faure
+33 (0)1 44 71 94 94
KEYWORD: UNITED STATES EUROPE NORTH AMERICA FRANCE NEW YORK
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL
Copyright Business Wire 2018.
PUB: 09/11/2018 03:30 PM/DISC: 09/11/2018 03:30 PM